Massachusetts General Hospital coordinated the first four platform trials within the HEALEY ALS platform to evaluate ...
Medpage Today on MSN2d
Two Investigational Treatments for ALS Show Glimmer of HopeThe first four treatments in a platform trial for amyotrophic lateral sclerosis (ALS) failed to reach key endpoints in phase ...
News Medical on MSN1d
Study of familial ALS in Egypt reveals that genetic variations may contribute to disease progressionAmyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease characterized by the progressive degeneration ...
News Medical on MSN2d
Groundbreaking ALS platform trial accelerates research and drug testingAmyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with few treatment options. Since 2018, the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH), a ...
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with few treatment options. Since 2018, the Sean M.
Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) is expected to be releasing its earnings data before the market opens ...
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Voyager ...
Scientists have developed a lipid nanoparticle system capable of delivering messenger RNA (mRNA) to the brain via intravenous injection, a challenge that has long been limited by the protective nature ...
The Baylor Medicine ALS Multidisciplinary Clinic is a leading institution dedicated to comprehensive care for patients with Amyotrophic Lateral Sclerosis (ALS) in the Greater Houston area and beyond.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback